Evaluation value of systemic immune inflammatory index on major adverse cardiac events in patients with AECOPD

HAO Wenwen; LI Zhensheng; LIU Yueqiao; SHI Jingjing; DU Dongqin; WANG Guowei; LI Xiaojing

PDF(2251 KB)

Journal of Hunan Normal University(Medical Science) ›› 2025, Vol. 22 ›› Issue (1) : 55-59.

Clinical Medicine

Evaluation value of systemic immune inflammatory index on major adverse cardiac events in patients with AECOPD

HAO Wenwen¹, LI Zhensheng², LIU Yueqiao², SHI Jingjing³, DU Dongqin³, WANG Guowei⁴, LI Xiaojing⁵

Author information +

History +

Abstract

Objective To explore the evaluation value of systemic immune inflammatory index (SII) on major adverse cardiac events (MACE) in patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Methods This study was a retrospective cohort study. From January 2020 to January 2023, 376 AECOPD patients hospitalized in our hospital were recruited as the research object. The main outcome was the time when MACE appeared within 180 days after SII measurement. All patients were examined by routine blood tests after admission and SII was calculated. Results MACE events occurred in 35 patients (9.3%) within 180 days after discharge, including 22 cases of nonfatal myocardial infarction, 5 cases of target vessel revascularization and 8 cases of unstable angina requiring hospitalization. Compared with patients without MACE, the age, heart rate, the number of patients complicated with liver diseases, heart failure and chronic kidney disease, the number of patients receiving non-invasive mechanical ventilation and invasive mechanical ventilation, the levels of SII and high-sensitivity troponin (hsTrop) increased significantly, and the average systolic blood pressure, albumin and hematocrit decreased significantly. Multivariate analysis showed that SII (HR=1.004, 95%CI: 1.003-1.005) could be used as an independent influencing factor of MACE. The risk of MACE events in patients was compared according to the quartile of SII. The results showed that the incidence of MACE events in T1 to T3 group increased significantly [Log Rank (Mantel-Cox)=29.655, P<0.001], and the risk of MACE events in T3 group increased by 6.4 times and 5.2 times compared with that in T1 and T2 groups. There was a significant positive correlation between hsTrop level and SII level at admission (r=0.248, P<0.001). ROC analysis shows that the AUC of SII (cut-off value was 552) in predicting MACE events was 0.792(95%CI: 0.701-0.884), with sensitivity of 74.3% and specificity of 71.3%. Conclusion The increase of SII level may be a useful tool to predict MACE events in patients with AECOPD.

Key words

systemic immune inflammatory index / acute exacerbation of chronic obstructive pulmonary disease / major adverse cardiac events / high-sensitivity troponin

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

HAO Wenwen, LI Zhensheng, LIU Yueqiao, SHI Jingjing, DU Dongqin, WANG Guowei, LI Xiaojing. Evaluation value of systemic immune inflammatory index on major adverse cardiac events in patients with AECOPD[J]. Journal of Hunan Normal University(Medical Science). 2025, 22(1): 55-59

References

[1] MAROTT J L, ÇOLAK Y, INGEBRIGTSEN T S, et al.Exacerbation history, severity of dyspnoea and maintenance treatment predicts risk of future exacerbations in patients with COPD in the general population[J]. Respir Med, 2022, 192: 106725.
[2] WHITTAKER H, ROTHNIE K J, QUINT J K.Exploring the impact of varying definitions of exacerbations of chronic obstructive pulmonary disease in routinely collected electronic medical records[J]. Plos one, 2023, 18(11): e0292876.
[3] MÜLLEROVÁ H, MARSHALL J, DE NIGRIS E, et al. Association of COPD exacerbations and acute cardiovascular events: a systematic review and meta-analysis[J]. Ther Adv Respir Dis, 2022, 16: 17534666221113647.
[4] XU H, TAN J H, ABISHEGANADEN J A, et al.Conventional vs high-sensitive troponins in acute exacerbations of chronic obstructive pulmonary disease[J]. Heart Lung, 2021, 50(3): 430-436.
[5] CASS S P, COPE A P, NICOLAU D V, et al.Moving the pathway goalposts: COPD as an immune-mediated inflammatory disease[J]. Lancet Respir Med, 2022, 10(12): 1110-1113.
[6] SU G, ZHANG Y, XIAO R, et al.Systemic immune-inflammation index as a promising predictor of mortality in patients with acute coronary syndrome: a real-world study[J]. J Int Med Res, 2021, 49(5): 03000605211016274.
[7] HAI T, WU W, REN K, et al.Prognostic significance of the systemic immune-inflammation index in patients with extranodal natural killer/T-cell lymphoma[J]. Front Oncol, 2023, 13: 1273504.
[8] SONG R, NI H, HUANG J, et al.Prognostic Value of Inflammation-Immunity-Nutrition Score and Inflammatory Burden Index for Hepatocellular Carcinoma Patients After Hepatectomy[J]. J Inflamm Res, 2022, 15: 6463-6479.
[9] YE Z, HU T, WANG J, et al.Systemic immune-inflammation index as a potential biomarker of cardiovascular diseases: A systematic review and meta-analysis[J]. Front Cardiovasc Med, 2022, 9: 933913.
[10] ZHAO Y, SHAO W, ZHU Q, et al.Association between systemic immune-inflammation index and metabolic syndrome and its components: results from the National Health and Nutrition Examination Survey 2011-2016[J]. J Transl Med, 2023, 21(1): 691.
[11] AGUSTÍ A, CELLI B R, CRINER G J, et al.Global initiative for chronic obstructive lung disease 2023 report: GOLD executive summary[J]. Am J Respir Crit Care Med, 2023, 207(7): 819-837.
[12] CELLI B R, FABBRI L M, AARON S D, et al.Differential Diagnosis of Suspected Chronic Obstructive Pulmonary Disease Exacerbations in the Acute Care Setting: Best Practice[J]. Am J Respir Crit Care Med, 2023, 207(9): 1134-1144.
[13] ESENBOĞA K, KURTUL A, YAMANTÜRK Y Y, et al. Comparison of systemic immune-inflammation index levels in patients with isolated coronary artery ectasia versus patients with obstructive coronary artery disease and normal coronary angiogram[J]. Scand J Clin Lab Invest, 2022, 82(2): 132-137.
[14] SHI S, KONG S, NI W, et al.Association of the Systemic Immune-Inflammation Index with Outcomes in Acute Coronary Syndrome Patients with Chronic Kidney Disease[J]. J Inflamm Res, 2023, 16: 1343-1356.
[15] XIE R, XIAO M, LI L, et al.Association between SII and hepatic steatosis and liver fibrosis: A population-based study[J]. Front Immunol, 2022, 13: 925690.
[16] XU Y, YAN Z, LI K, et al.The association between systemic immune-inflammation index and chronic obstructive pulmonary disease in adults aged 40 years and above in the United States: a cross-sectional study based on the NHANES 2013-2020[J]. Front Med, 2023, 10: 1270368.
[17] YE C L, YUAN L, WU K L, et al.Association between systemic immune-inflammation index and chronic obstructive pulmonary disease: a population-based study[J]. BMC Pulm Med, 2023, 23(1): 295.
[18] BENZ E, WIJNANT S R A, TRAJANOSKA K, et al. Sarcopenia, systemic immune-inflammation index and all-cause mortality in middle-aged and older people with COPD and asthma: a population-based study[J]. ERJ Open Res, 2022, 8(1): 00628-2021.
[19] BHATNAGAR R, BERGE K, RØYSLAND R, et al. Cardiac troponin T and NT-proBNP for prediction of 30-day readmission or death in patients with acute dyspnea: data from the Akershus Cardiac Examination 2 Study[J]. Cardiology, 2023, 148(6): 506-516.
[20] DEREBEY S T, TOKGÖZ H C, KESKIN B, et al. A New Index for the Prediction of In-Hospital Mortality in Patients with Acute Pulmonary Embolism: The Modified Shock Index[J]. Anatol J Cardiol, 2023, 27(5): 282-289.
[21] KALLIS C, KAURA A, SAMUEL N A, et al.The Relationship Between Cardiac Troponin in People Hospitalised for Exacerbation of COPD and Major Adverse Cardiac Events (MACE) and COPD Readmissions[J]. Int J Chron Obstruct Pulmon Dis, 2023, 18: 2405-2416.